AU2002328897A1 - Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours - Google Patents

Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours

Info

Publication number
AU2002328897A1
AU2002328897A1 AU2002328897A AU2002328897A AU2002328897A1 AU 2002328897 A1 AU2002328897 A1 AU 2002328897A1 AU 2002328897 A AU2002328897 A AU 2002328897A AU 2002328897 A AU2002328897 A AU 2002328897A AU 2002328897 A1 AU2002328897 A1 AU 2002328897A1
Authority
AU
Australia
Prior art keywords
gene
gene therapy
tumours
metastases
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002328897A
Other languages
English (en)
Inventor
Karsten Brand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CUSTOS BIOTECHNOLOGIE GmbH
Original Assignee
CUSTOS BIOTECHNOLOGIE GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10159128A external-priority patent/DE10159128A1/de
Application filed by CUSTOS BIOTECHNOLOGIE GmbH filed Critical CUSTOS BIOTECHNOLOGIE GmbH
Publication of AU2002328897A1 publication Critical patent/AU2002328897A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002328897A 2001-07-13 2002-07-15 Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours Abandoned AU2002328897A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10133560 2001-07-13
DE10133560.1 2001-07-13
DE10159128.4 2001-12-01
DE10159128A DE10159128A1 (de) 2001-07-13 2001-12-01 Genregulatorische Elemente zur Gentherapie, zur Prävention und Diagnose von Metastasen bzw. zur Gentherapie von Tumoren
PCT/EP2002/007857 WO2003006657A2 (fr) 2001-07-13 2002-07-15 Elements de regulation du gene destines a la therapie genique pour la prevention et le diagnostic de metastases ainsi que le traitement des tumeurs par therapie genique

Publications (1)

Publication Number Publication Date
AU2002328897A1 true AU2002328897A1 (en) 2003-01-29

Family

ID=26009675

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002328897A Abandoned AU2002328897A1 (en) 2001-07-13 2002-07-15 Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours

Country Status (2)

Country Link
AU (1) AU2002328897A1 (fr)
WO (1) WO2003006657A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329055T1 (de) * 1998-11-05 2006-06-15 Ortho Mcneil Pharm Inc Methode zur erstellung von genexpressionsprofilen
WO2000061806A2 (fr) * 1999-04-09 2000-10-19 Arcturus Engineering, Inc. Reseau generique d'adnc ou de proteines destine a des bioanalyses personnalisees
WO2000066176A2 (fr) * 1999-04-30 2000-11-09 Karsten Brand Agent pour la therapie genique et la prevention de metastases ainsi que pour la therapie genique de tumeurs

Also Published As

Publication number Publication date
WO2003006657A3 (fr) 2003-11-13
WO2003006657A2 (fr) 2003-01-23

Similar Documents

Publication Publication Date Title
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002350235A1 (en) Combination bacteriolytic therapy for the treatment of tumors
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
IL157425A0 (en) Treatment of solid tumours with paramycin derivatives
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2002254482A1 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2002326356A1 (en) Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
AU2002240336A1 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002258728A1 (en) Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002349543A1 (en) Tumor antigens
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002342053A1 (en) Pancreatic cancer diagnosis and therapies
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002304883A1 (en) Device for the treatment of tumours
AU2002328897A1 (en) Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase